

V3.0 December 2021

Saturday 12 February

Welcome

Room: Plenary

- 0830** **Opening address**
Guest speaker
- 0850** **2021 Melanoma Summit overview**
Dr Chris Boberg, Chair, 2021 New Zealand Melanoma Summit Planning Committee and Co-Chair, MelNet
- 0855** **Patient challenge**
Terence Walsh, Patient representative
- 0910** **Melanoma in the New Zealand cancer landscape**
Dr Chris Jackson, Chair, Cancer Control Agency Clinical Assembly and Medical Oncologist, Southern District Health Board
- 0940** **Quality Statements to Guide Melanoma Diagnosis and Treatment in New Zealand**
Mr Richard Martin, Surgical Oncologist, New Zealand Melanoma Unit, Waitemata District Health Board and Chair, Melanoma Quality Statements Working Group
- 1000** **Morning tea**

Session 1: Epidemiology and primary prevention

Chair: Dr Rosalie Stephens, Medical Oncologist, Auckland District Health Board Oncology Services and Melanoma New Zealand Trustee **Room:** Plenary

- 1030** **Epidemiological trends in melanoma**
Professor David Whiteman, Deputy Director, Head of Cancer Control Laboratory and Coordinator, Melanoma and Skin Cancer Research Centre, QIMR Berghofer Medical Research Institute, Queensland, Australia
- 1055** **What is happening about sunscreens in New Zealand?**
Jon Duffy, Chief Executive, Consumer New Zealand
Dr Louise Reiche, Dermatologist, Kauri Healthcare Palmerston North and Immediate Past President, New Zealand Dermatological Society Incorporated
- 1120** **My story**
Todd Muller, Patient representative
- 1130** **Questions and discussion**

Session 2: The economics of the skin cancer epidemic

Chair: Mr Gary Duncan, Consultant Plastic and Reconstructive Surgeon, Boulcott and Hutt Hospitals and Co-Chair, MelNet **Room:** Plenary

- 1140** **The escalating burden of skin cancer to Government**
Associate Professor Louisa Gordon, Group Leader Health Economics
QIMR Berghofer Medical Research Institute
Kindly sponsored by La Roche-Posay
- 1200** **A private perspective on the burden of skin cancer**
Dr Stephen Child, Chief Medical Officer, Southern Cross
- 1220** **Questions and discussion**

1230 Lunch

Session 3: Early detection

Chair: Dr Chris Boberg, GP with special interest in skin cancer and President NZ Skin Cancer Doctors Society

Room: Plenary

1330 **Early detection saves lives: our story**

Chris and Judy Bailey, Patient representatives

1340 **The evolution of early detection, dermatoscopy and artificial intelligence**

Professor Cliff Rosendahl, Course Coordinator of the Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia

Adjunct Associate Professor Amanda Oakley, Dermatologist, Waikato District Health Board

1415 **Questions and discussion**

1430 **Session 4: Concurrent breakout session 1**

[4A] Skin cancer screening

Chair: Dr Chris Jackson, Chair, Cancer Control Agency Clinical Assembly and Medical Oncologist, Southern District Health Board

Room: One

This session will look at different methods of skin cancer screening. It will highlight screening initiatives in the sector and discuss how data captured through these initiatives could be used to support wider work.

Presenters:

Professor David Whiteman, Deputy Director, Head of Cancer Control Laboratory and Coordinator, Melanoma and Skin Cancer Research Centre, QIMR Berghofer Medical Research Institute, Queensland, Australia

TBC

[4B] Dermatoscopy in action

Chair: Dr Chris Boberg, GP with special interest in skin cancer and President New Zealand Skin Cancer Doctors Society

Room: Two

This session will teach the basics of the 'chaos and clues' approach to dermatoscopy in diagnosing melanoma and will demonstrate its practical application to specific cases.

Presenter:

- **Professor Cliff Rosendahl**, Course Coordinator of the Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia

[4C] MelNet melanoma multi-disciplinary meeting: challenging cases

Chair: Mr Richard Martin, Surgical Oncologist, New Zealand Melanoma Unit, Waitemata District Health Board

Room: Three

In this session, a multi-disciplinary panel will discuss the clinical management of a range of challenging or unusual cases of melanoma.

Panel:

- **Dr Jody Jordan**, Medical Oncologist, Hawke's Bay District Health Board and Canopy Cancer Care, Hastings
- **Dr Reinhard Gansel**, Dermatologist, Waikato District Health Board
- **Susan Millmow**, Clinical Nurse Specialist/Cancer Nurse Coordinator, Hutt Valley District Health Board
- **Mr Richard Martin**, Surgical Oncologist, New Zealand Melanoma Unit, Waitemata District Health Board
- **Dr Anthony Tam**, General Practitioner with special interest in skin cancer, Skinsite, Auckland

[4D] Upcoming research and innovations

Chair: Adjunct Associate Professor Amanda Oakley, Dermatologist, Waikato District Health Board

Room: Four

Presenters whose submitted abstracts have been selected will provide snapshots of upcoming research and clinical innovations.

Presenters:

- **Dr Harmony Thompson**, Medical Registrar, Waikato Hospital and University of Auckland
Artificial Intelligence Support for Skin Lesion Triage in Primary Care and Dermatology
- **Dr Michel Nieuwoudt**, Senior Research Fellow, University of Auckland, MacDiarmid Institute for Advanced Materials and Nanotechnology and Dodd-Walls Centre for Photonic and Quantum Technologies
Non-invasive and in vivo measurement of skin lesions using Raman spectroscopy
- **Dr Leah Jones**, Dermatology Registrar, Waikato District Health Board and University of Auckland
GP referrals with images of skin lesions leads to effective skin cancer diagnosis compared to nurse-led imaging
- **Dr Ken Hiu-Kan Ip**, Dermatology Registrar, Auckland District Health Board
Multidisciplinary Pigmented Lesion Clinic at Auckland District Health Board: Impacts on melanoma diagnosis and treatment outcomes
- **Thu Thu Win Myint**, Master of Public Health student, University of Auckland
The risk of subsequent invasive melanoma in patients following initial in-situ or invasive melanoma, 2001-2017
- **Dr Hayley Reynolds**, Senior Research Fellow, Auckland Bioengineering Institute, University of Auckland
Advanced 3D software tools to predict sentinel node locations from sites of cutaneous melanoma
- **Dr Daniel Wen**, House Officer, Waitemata District Health Board
Proposed quality performance indicators of sentinel lymph node biopsy for cutaneous melanoma
- **Professor Michael Eccles**, Researcher, Department of Pathology, University of Otago and Maurice Wilkins Centre for Molecular Biodiscovery, Auckland
Investigation of potential genomic biomarkers for predicting response to immunotherapy treatment in melanoma patients

1530

Afternoon tea

Session 5: Paving the way for high quality, collaborative melanoma care

Chair: Mr Gary Duncan, Consultant Plastic and Reconstructive Surgeon, Boulcott and Hutt Hospitals and Co-Chair, MelNet

Room: Plenary

1600

Waitemata District Health Board: a collaborative skin cancer care model

Dr Daniel Wen, House Officer, Waitemata District Health Board

1620

Nurse led dermatoscopy clinics: the way of the future?

Katy Doherty, Managing Director, Espy Skin, Auckland

Trish Baker, Managing Director, Healthbox NZ Ltd, Auckland

1635

Serious Illness Conversation Guide

Jane Goodwin, Advance Care Planning Facilitator, Health Quality and Safety Commission and Registered Nurse, Canterbury District Health Board

1700

Session 6: Concurrent breakout session 2

[6A] Pathology synoptic reporting and histology update

Chair: Dr Richard Massey, Pathologist and Director of Pathology Associates, Tauranga

Room: One

This session will update on progress towards consistent synoptic reporting for skin cancer.

Presenters:

- **Dr Richard Massey**, Pathologist and Director of Pathology Associates, Tauranga
- **Dr Michael Hitchcock**, Pathologist and Clinical Lead, Anatomic Pathology Services, Auckland District Health Board

[6B] New Zealand melanoma research and therapy special interest group

Co-Chairs: **Dr Annie Wong**, Medical Oncologist, Capital Coast District Health Board and **Dr Jody Jordan**, Medical Oncologist, Hawke's Bay District Health Board and Canopy Cancer Care, Hastings

Room: Two

Intended for those involved or interested in being part of the Melanoma Research and Therapy Special Interest Group or those with an interest in research or therapy.

Presenters:

- **Dr Stephanie Savage**, Plastic Surgery Registrar, Waikato Hospital
Changing landscape of melanoma management: the impact of adjuvant systemic therapy on surgical management of stage II melanoma
- **Dr Sean Sutton**, Medical Oncology Registrar, Capital and Coast District Health Board
Management of metastatic melanoma with cerebral metastases at Wellington Regional Hospital

[6C] Serious Illness Conversation Guide

Chair: Nicola Hobbs, Cancer Nurse Coordinator, Canterbury District Health Board

Room: Three

Using the Serious Illness Conversation Guide, this session will build on the plenary session to help to develop skills and confidence in having difficult conversations with patients and their whānau.

Presenter:

- **Jane Goodwin**, Advanced Care Planning Facilitator and Registered Nurse, Canterbury District Health Board

[6D] GPs with a special interest in skin cancer

Chair: Dr Chris Boberg, President, New Zealand Skin Cancer Doctors Society

Room: Four

Intended for those who are part of or interested in joining New Zealand Skin Cancer Doctors Society. The session will provide an overview of New Zealand Skin Cancer Doctors Society and the work they do. It will also include a discussion of interesting dermatoscopic and surgical cases. Attendees are encouraged to bring along cases to discuss.

1730

Day 1 close

Level 1

Sunday 13 February

Session 7: Controversy of borderline lesions

Chair: Dr Richard Massey, Pathologist and Director of Pathology Associates, Tauranga

Room: Plenary

0830

Clinico-histological collaboration

Professor Cliff Rosendahl, Course Coordinator of the Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia

Dr Ben Tallon, Dermatologist, SKIN Dermatology Institute and Dermatopathologist, Pathlab, Tauranga

Dr Richard Massey, Pathologist and Director of Pathology Associates, Tauranga

Dr Michael Hitchcock, Pathologist and Clinical Lead, Anatomic Pathology Services, Auckland District Health Board

0850

Questions and discussion

Session 8: State of the art melanoma management

Chair: Mr Gary Duncan, Consultant Plastic and Reconstructive Surgeon, Boulcott and Hutt Hospitals and Co-Chair, MelNet

Room: Plenary

0900

My story

Dr Jeff Dalley, Patient representative

0915

In situ melanoma – current best practice in New Zealand

Dr Andrew MacGill, Director, SkinCheck Northcote, Auckland and fully accredited member of New Zealand Skin Cancer Doctors Society

0930

Mohs surgery for melanoma

Dr Paul Salmon, Dermatologist, Skin Centre Tauranga and Auckland Dermatology

0945

The current role of sentinel node biopsy in managing primary melanoma

Dr Mark Faries, Professor of Surgery and Co-Director Cutaneous Oncology Program, The Angeles Clinic and Research Institute and Cedars-Sinai Medical Center, Los Angeles, USA

1015

Questions and discussion

1030

Morning tea

Session 9: Advanced melanoma management

Chair: Dr Jody Jordan, Medical Oncologist, Hawke's Bay District Health Board and Canopy Cancer Care, Hastings

Room: Plenary

1100

My story

Tim Stevens, Patient representative

1115

The evolution of adjuvant and neoadjuvant therapy

Dr Inês Pires da Silva, Medical Oncologist and Researcher Scientist at Melanoma Institute Australia, Westmead and Blacktown Hospitals, and University of Sydney

1145

The New Zealand situation

Dr Jody Jordan, Medical Oncologist, Hawke's Bay District Health Board and Canopy Cancer Care, Hastings

1200

Nurses care perspective on managing advanced melanoma

Jo Tuaine, Oncology Clinical Nurse Specialist, Southern Blood and Cancer Service, Southern District Health Board

1215

Questions and discussion

1230

Lunch

Session 10: Melanoma and genetics

Chair: Dr Annie Wong, Medical Oncologist, Capital Coast District Health Board

Room: Plenary

1330 The current status of molecular profiling of melanoma

Professor Grant McArthur, Head Molecular Oncology Laboratory, Peter MacCallum Cancer Centre and Executive Director, Victoria Comprehensive Cancer Centre, Melbourne, Australia

1350 Questions and discussion

1400 Session 11: Concurrent breakout session 3

[11A] Priorities for action – primary prevention

Chair: Dr Bronwen McNoe, Senior Research Fellow and Co-Director, Social and Behaviour Research Unit, University of Otago

Room: One

This session will workshop priorities for action for New Zealand that support primary prevention.

[11B] Priorities for action – early detection

Chair: Dr Chris Boberg, GP with special interest in skin cancer and President NZ Skin Cancer Doctors Society

Room: Two

This session will workshop priorities for action for New Zealand that support early detection

[11C] Priorities for action – clinical management of advanced disease and research

Co-Chairs: **Dr Annie Wong**, Medical Oncologist, Capital Coast District Health Board and **Dr Jody Jordan**, Medical Oncologist, Hawke's Bay District Health Board and Canopy Cancer Care, Hastings

Room: Three

This session will workshop priorities for action for New Zealand relating to the clinical management of advanced disease and research.

Session 12: Looking to the future of melanoma

Co-Chairs: Dr Chris Boberg and Mr Gary Duncan, Co-Chairs, MelNet

Room: Plenary

1430 Setting the priorities for action – recommendations from breakout session 3

Dr Bronwen McNoe, Senior Research Fellow and Co-Director, Social and Behaviour Research Unit, University of Otago

Dr Chris Boberg, GP with special interest in skin cancer and President NZ Skin Cancer Doctors Society

Dr Annie Wong, Medical Oncologist, Capital Coast District Health Board

Dr Jody Jordan, Medical Oncologist, Hawke's Bay District Health Board and Canopy Cancer Care, Hastings

1450 Patient perspective – the final say

Chris and Judy Bailey, Patient representatives

Dr Jeff Dalley, Patient representative

Tim Stevens, Patient representative

Terence Walsh, Patient representative

1530 Wrap up and closing remarks

Mr Gary Duncan and Dr Chris Boberg, Co-Chairs, MelNet

1545 Close